The antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice
Christina T. Saed(University of Alberta), John R. Ussher(University of Alberta), Kunyan Yang(University of Alberta), Farah Eaton(University of Alberta), Amanda A. Greenwell(University of Alberta), Jordan S. F. Chan(University of Alberta), Rami Al Batran(Université de Montréal), Keshav Gopal(University of Alberta), Seyed Amirhossein Tabatabaei Dakhili(University of Alberta)
Cited by 1
Related Papers
Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency
|Cardiovascular Research|2019|195
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
|Diabetes|2022|62
Cardiac-Specific Deletion of Pyruvate Dehydrogenase Impairs Glucose Oxidation Rates and Induces Diastolic Dysfunction
|Frontiers in Cardiovascular Medicine|2018|42
The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity
|JCI Insight|2019|18
Ketone ester administration improves glycemia in obese mice
|American Journal of Physiology-Cell Physiology|2023|18